Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: January 2025 (Filed January 6, 2025)
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of corporate governance changes rather than a financial statement.
Material Changes
The primary material change disclosed in this filing is the submission of four "Change of Director's Interest Notice" exhibits (Exhibit 99.1). No other operational or financial changes are detailed in the provided text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves solely to incorporate the Director's Interest Notices into existing Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Review the four attached "Change of Director's Interest Notice" exhibits to understand specific changes in director holdings.
- Verify the impact of these changes on the company's governance structure.
- Consult the referenced Registration Statements (Form S-8 and Form F-3) for broader context on capital raising activities.
- Note that no financial performance data is included in this specific filing.